No connection

Search Results

KRRO vs RNAC

KRRO
Korro Bio, Inc.
BEARISH
Price
$12.68
Market Cap
$182.9M
Sector
Healthcare
AI Confidence
85%
RNAC
Cartesian Therapeutics, Inc.
BEARISH
Price
$7.04
Market Cap
$186.6M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
KRRO
--
RNAC
--
Forward P/E
KRRO
-1.67
RNAC
-4.17
P/B Ratio
KRRO
2.32
RNAC
-1.45
P/S Ratio
KRRO
28.61
RNAC
66.72
EV/EBITDA
KRRO
-1.82
RNAC
-0.89

Profitability

Gross Margin
KRRO
0.0%
RNAC
0.0%
Operating Margin
KRRO
-1229.33%
RNAC
-2316.68%
Profit Margin
KRRO
0.0%
RNAC
0.0%
ROE
KRRO
-110.7%
RNAC
--
ROA
KRRO
-32.14%
RNAC
-14.82%

Growth

Revenue Growth
KRRO
-43.1%
RNAC
--
Earnings Growth
KRRO
--
RNAC
--

Financial Health

Debt/Equity
KRRO
0.85
RNAC
--
Current Ratio
KRRO
6.9
RNAC
8.65
Quick Ratio
KRRO
6.38
RNAC
8.45

Dividends

Dividend Yield
KRRO
--
RNAC
--
Payout Ratio
KRRO
0.0%
RNAC
0.0%

AI Verdict

KRRO BEARISH

KRRO exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. While the company maintains a strong liquidity position with a current ratio of 6.90, this is offset by an extreme operating margin of -1229.33% and negative revenue growth of -43.10%. The stock is in a heavy technical downtrend, having lost over 70% of its value in the last six months. Despite a bullish analyst target of $20.00, the deterministic data suggests a high-risk speculative profile with no current path to profitability.

Strengths
Strong short-term liquidity (Current Ratio: 6.90)
Recent trend of beating EPS estimates (2/4 last quarters)
Significant upside gap to analyst target price ($20.00)
Risks
Extreme cash burn reflected in -1229.33% operating margin
Severe revenue contraction (-43.10% YoY)
Critical fundamental health (Piotroski F-Score: 1/9)
RNAC BEARISH

RNAC exhibits severe financial distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in nearly all fundamental health categories. The company suffers from negative equity (Price/Book of -1.45) and an unsustainable operating margin of -2316.68%. While analysts maintain a 'strong_buy' rating with a target of $35.57, this is completely decoupled from the current financial reality of massive earnings misses and negative EPS growth. The combination of insider selling by the CEO and CFO and a 5-year price collapse of 93.8% suggests a high-risk speculative profile.

Strengths
Strong short-term liquidity with a Current Ratio of 8.65
High analyst conviction (Strong Buy consensus)
Recent short-term price momentum (1-week gain of 17.7%)
Risks
Negative shareholder equity (P/B -1.45)
Extreme valuation relative to sales (P/S 66.72)
Severe operational inefficiency (Operating Margin -2316.68%)

Compare Another Pair

KRRO vs RNAC: Head-to-Head Comparison

This page compares Korro Bio, Inc. (KRRO) and Cartesian Therapeutics, Inc. (RNAC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile